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Summary
Background Low plasma 25-hydroxyvitamin D (25[OH]D) concentration is associated with high arterial blood pressure 
and hypertension risk, but whether this association is causal is unknown. We used a mendelian randomisation 
approach to test whether 25(OH)D concentration is causally associated with blood pressure and hypertension risk.
Methods In this mendelian randomisation study, we generated an allele score (25[OH]D synthesis score) based on 
variants of genes that aﬀ ect 25(OH)D synthesis or substrate availability (CYP2R1 and DHCR7), which we used as a 
proxy for 25(OH)D concentration. We meta-analysed data for up to 108 173 individuals from 35 studies in the D-CarDia 
collaboration to investigate associations between the allele score and blood pressure measurements. We complemented 
these analyses with previously published summary statistics from the International Consortium on Blood Pressure 
(ICBP), the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, and the Global 
Blood Pressure Genetics (Global BPGen) consortium.
Findings In phenotypic analyses (up to n=49 363), increased 25(OH)D concentration was associated with decreased 
systolic blood pressure (β per 10% increase, –0·12 mm Hg, 95% CI –0·20 to –0·04; p=0·003) and reduced odds of 
hypertension (odds ratio [OR] 0·98, 95% CI 0·97–0·99; p=0·0003), but not with decreased diastolic blood pressure 
(β per 10% increase, –0·02 mm Hg, –0·08 to 0·03; p=0·37). In meta-analyses in which we combined data from 
D-CarDia and the ICBP (n=146 581, after exclusion of overlapping studies), each 25(OH)D-increasing allele of the 
synthesis score was associated with a change of –0·10 mm Hg in systolic blood pressure (–0·21 to –0·0001; p=0·0498) 
and a change of –0·08 mm Hg in diastolic blood pressure (–0·15 to –0·02; p=0·01). When D-CarDia and consortia 
data for hypertension were meta-analysed together (n=142 255), the synthesis score was associated with a reduced 
odds of hypertension (OR per allele, 0·98, 0·96–0·99; p=0·001). In instrumental variable analysis, each 10% increase 
in genetically instrumented 25(OH)D concentration was associated with a change of –0·29 mm Hg in diastolic blood 
pressure (–0·52 to –0·07; p=0·01), a change of –0·37 mm Hg in systolic blood pressure (–0·73 to 0·003; p=0·052), 
and an 8·1% decreased odds of hypertension (OR 0·92, 0·87–0·97; p=0·002).
Interpretation Increased plasma concentrations of 25(OH)D might reduce the risk of hypertension. This ﬁ nding 
warrants further investigation in an independent, similarly powered study.
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Introduction
Low vitamin D status has been associated with an 
increased risk of cardiovascular disease and all-cause 
mortality, and the possible beneﬁ ts of vitamin D 
supplementation are being actively investigated and 
debated.1,2 In observational studies, low plasma 
25-hydroxy vitamin D (calcidiol, 25[OH]D) concentration 
is associated with an increased risk of hypertension.3 
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However, few large randomised controlled trials of 
vitamin D supplementation with primary cardiovascular 
outcomes have been done, and secondary analyses from 
other trials have provided little evidence to support an 
eﬀ ect of vitamin D supplementation on cardiovascular 
outcomes.1,4,5 The largest of the randomised controlled 
studies was the Women’s Health Initiative trial4 
(n=36 282), the results of which did not show any changes 
in blood pressure or hypertension after 7 years of 
follow-up.4 However, the vitamin D dose used in that trial 
was quite small (400 IU per day), and women in both 
treatment and placebo groups were allowed to take up to 
1000 IU per day of additional open-label vitamin D 
supplementation. Some evidence for possible eﬀ ects of 
vitamin D supplementation on blood pressure has been 
obtained from randomised controlled trials with higher 
doses6 and those investigating individuals with cardio-
metabolic risk;5 however, as Elamin and colleagues have 
previously noted,7 the quality of the available evidence is 
“low to moderate at best”.
In this study, we explored the possible causal relation 
between vitamin D status and blood pressure and 
hypertension using a genetic approach. Mendelian 
randomisation exploits the fact that individual genotypes 
are assigned randomly at meiosis, so the eﬀ ect of genetics 
on disease is generally unaﬀ ected by confounding or 
reverse causality.8 Recent genome-wide association studies 
(GWAS) have identiﬁ ed several variants that aﬀ ect 
circulating concentrations of 25(OH)D.9 If 25(OH)D 
concentrations are causally involved in determining blood 
pressure or the risk of hypertension, then the genetic 
variants that aﬀ ect circulating concentrations of 25(OH)D 
could be expected to aﬀ ect blood pressure and hypertension 
risk. This assumption seems to be valid for at least two of 
the genes that aﬀ ect 25(OH)D, namely CYP2R1 (encoding 
cytochrome P450, family 2, subfamily R, polypeptide 1) 
and DHCR7 (encoding 7-dehydrocholesterol reductase). 
These genes function upstream of 25(OH)D production 
and aﬀ ect vitamin D synthesis or substrate availability.10,11 
Two further downstream variants aﬀ ect 25(OH)D, GC 
(encoding group-speciﬁ c component [vitamin D binding 
protein]) and CYP24A1 (encoding cytochrome P450, 
family 24, subfamily A, polypeptide 1), but both are known 
to have pleiotropic eﬀ ects.12,13 In this study, we used genetic 
variants that aﬀ ect vitamin D synthesis as proxy markers 
for lifelong diﬀ erences in vitamin D status to test for a 
causal association with blood pressure and hypertension.
Methods
Study design and population
We used a mendelian randomisation approach to 
investigate the association between genetic variants that 
aﬀ ect concentrations of circulating 25(OH)D and blood 
pressure measurements. We meta-analysed data from 
35 studies in the D-CarDia collaboration, with results 
complemented by previously published summary 
statistics from other large-scale consortium eﬀ orts.14–16 
D-CarDia is a collaboration of studies, consisting of 
cohorts of European ancestry from Europe and North 
America, that investigates the association of vitamin D 
and the risk of cardiovascular disease and related traits.11 
We meta-analysed directly genotyped and imputed 
single-nucleotide polymorphisms (SNPs) from 31 adult 
(aged 31–92 years, n=99 582) and four adolescent 
(aged 10–20 years, n=8591) cohorts in the D-CarDia 
collaboration (table 1, ﬁ gure 1). All participants provided 
written informed consent, and all participating studies 
received approval from local research ethics committees. 
The appendix (pp 2−19) includes descriptions of all the 
studies included in the analysis.
To further increase the statistical power of our study, we 
meta-analysed our results in adults with data from the 
International Consortium for Blood Pressure (ICBP)14 
when examining systolic or diastolic blood pressure as 
the outcome (n=146 581, after exclusion of overlapping 
studies; ﬁ gure 1). At the time of the study, hypertension 
had not been formally examined as an outcome in the 
ICBP consortium, and related coeﬃ  cients were not 
available. Therefore, we used summary data from Cohorts 
for Heart and Aging Research in Genomic Epidemiology 
(CHARGE; n=29 136)16 and Global Blood Pressure 
Genetics (Global BPGen) (n=34 433)15 consortia when 
examining hypertension as the outcome (n=142 255 after 
exclusion of overlapping studies; ﬁ gure 1).
Phenotypic measures
Hypertension was deﬁ ned as systolic blood pressure of 
140 mm Hg or higher, diastolic blood pressure of 
90 mm Hg or higher, or current use of antihypertensive 
drugs. For participants taking antihypertensive drugs, we 
added 15 mm Hg to systolic and 10 mm Hg to diastolic 
blood pressure to correct for the eﬀ ect of the treatment.14
25(OH)D concentrations were available for 19 of the 
35 studies in the D-CarDia collaboration (n=51 122), with 
values expressed in nmol/L for all studies. The appendix 
(pp 2−19) includes details about the methods used to 
measure 25(OH)D concentration in each study.
Selection of SNPs and allele scores
To create vitamin D allele scores, we selected four vitamin 
D-related SNPs (DHCR7 rs12785878, CYP2R1 rs12794714, 
GC rs2282679, and CYP24A1 rs6013897) based on the 
results of the GWAS by the SUNLIGHT Consortium,9 with 
two SNPs in genes located upstream (DHCR7 and CYP2R1) 
and two downstream (GC and CYP24A1) of the 25(OH)D 
metabolite.10 All but one (CYP2R1) were selected as the top 
hit; for CYP2R1 we used an alternative SNP also identiﬁ ed 
by the GWAS by the SUNLIGHT Consortium (p=1·84 × 10–⁹ 
for association with 25[OH]D concentration) because it was 
a functional variant in moderate linkage disequilibrium 
(r²=0·41) with the ﬁ rst-stage GWAS top hit rs10741657.9 The 
appendix (pp 2–25) includes a detailed description of the 
genotyping and imputation methods and eﬀ ect allele 
frequencies for all the studies included in the meta-analysis.
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Sample size Men Women All participants
Age
(years)
Systolic 
blood 
pressure
(mm Hg)
Diastolic 
blood 
pressure
(mm Hg)
Participants 
with hyper-
tension
Age
(years)
Systolic 
blood 
pressure
(mm Hg)
Diastolic 
blood 
pressure
(mm Hg)
Participants 
with hyper-
tension
Age
(years)
Systolic 
blood 
pressure
(mm Hg)
Diastolic 
blood 
pressure
(mm Hg)
Participants 
with hyper-
tension
Studies in adults
NFBC 1966 4488
(2270 men, 
2218 women)
31·2
(0·4)
130·5
(13·2)
80·4
(11·7)
697
(31%)
31·2
(0·3)
120·5
(19·1)
75·4
(10·7)
280
(13%)
31·2
(0·3)
125·6
(13·9)
77·9
(11·5)
977
(22%)
Young Finns 2443
(1123 men, 
1320 women)
37·6
(5·1)
126·8
(14·2)
79·5
(11·8)
239
(21%)
37·6
(5·0)
117·6
(15·0)
74·0
(11·8)
167
(13%)
37·6
(5·1)
122·2
(14·6)
76·8
(11·8)
406
(17%)
NESDA 1717
(551 men, 
1166 women)
43·7
(12·3)
145·1
(19·5)
85·1
(12·0)
317
(58%)
40·5
(12·7)
130·6
(19·1)
80·0
(11·6)
336
(29%)
41·5
(12·3)
135·3
(19·2)
81·6
(11·7)
653
(38%)
1958BC 7152
(3525 men, 
3627 women)
45·0
(0·0)
133·7
(15·6)
82·6
(10·8)
1229
(35%)
45·0
(0·0)
120·9
(16·1)
75·9
(10·8)
580
(16%)
45·0
(0·0)
127·2
(17·1)
79·3
(11·3)
1809
(25%)
GOYA 1465
(1465 men, 
0 women)
45·6
(7·1)
143·3
(19·3)
93·4
(12·3)
986
(67%)
·· ·· ·· ·· 45·6
(7·1)
143·3
(19·3)
93·4
(12·3)
986
(67%)
FHS 5654
(2677 men, 
2977 women)
46·7
(12·9)
125·7
(17·1)
79·3
(10·4)
582
(22%)
46·2
(12·9)
118·4
(19·6)
73·7
(10·5)
778
(26%)
46·5
(12·9)
122·1
(18·4)
76·5
(10·5)
1360
(24%)
LifeLines 13 235
(5532 men, 
7703 women)
49·0
11·7)
135·6
(16·1)
79·7
(10·0)
2186
(40%)
48·5
(11·3)
127·3
(18·0)
74·8
(9·7)
2089
(27%)
48·7
(11·7)
130·8
(17·2)
76·8
(9·8)
4275
(32%)
SPLIT 498
(213 men, 
285 women)
47·9
(15·5)
134·4
(18·9)
80·9
(11·9)
80
(38%)
49·9
(13·9)
127·9
(21·4)
76·8
(12·5)
92
(32%)
49·1
(15·3)
131·2
(20·1)
78·9
(12·2)
172
(35%)
Twins UK 2392
(189 men, 
2203 women)
48·6
(12·4)
130·2
(14·1)
80·3
(9·9)
53
(28%)
49·1
(12·3)
121·8
(16·0)
76·8
(10·6)
488
(22%)
49·1
(12·4)
122·6
(16·4)
77·2
(10·8)
541
(25%)
PREVEND 3649
(1880 men, 
1769 women)
51·0
(13·0)
136·0
(20·0)
78·0
(11·0)
732
(39%)
48·0
(12·0)
125·0
(22·0)
72·0
(10·0)
479
(27%)
49·6
(12·9)
130·6
(21·0)
75·1
(10·5)
1211
(33%)
DOPS 1684
(0 men, 
1684 women)
·· ·· ·· ·· 50·1
(2·8)
131·8
(20·6)
83·0
(11·6)
743
(44%)
50·1
(2·8)
131·8
(20·6)
83·0
(11·6)
743
(44%)
GENMETS 868
(421 men, 
447 women)
49·2
(10·4)
131·6
(18·8)
83·2
(10·9)
157
(37%)
52·0
(11·6)
130·8
(20·9)
80·1
(11·1)
163
(36%)
50·7
(10·5)
131·2
(19·9)
81·6
(10·9)
320
(37%)
DPP 1998
(691 men, 
1307 women)
55·1
(10·9)
129·7
(16·5)
81·7
(11·0)
264
(38%)
50·4
(10·2)
124·9
(16·8)
78·8
(10·1)
335
(26%)
51·9
(10·9)
126·5
(16·7)
79·8
(10·4)
599
(30%)
MRC NSHD 2674
(1340 men, 
1334 women)
53·0
(0·0)
141·8
(21·3)
88·5
(13·1)
767
(57%)
53·0
(0·0)
134·6
(21·5)
832
(126)
574
(43%)
53·0
(0·0)
138·2
(21·4)
85·9
(12·9)
1341
(50%)
ORCADES 718
(334 men, 
384 women)
54·3
(15·7)
137·5
(19·8)
80·0
(10·7)
145
(43%)
53·0
(15·7)
130·1
(22·8)
77·1
(11·6)
136
(35%)
53·6
(15·7)
133·8
(21·3)
78·6
(11·2)
281
(39%)
NPHSII 2771
(2771 men, 
0 women)
56·1
(3·4)
139·7
(20·5)
85·4
(12·2)
1460
(53%)
·· ·· ·· ·· 56·1
(3·4)
139·7
(20·5)
85·4
(12·2)
1460
(53%)
KORCULA 901
(332 men, 
569 women)
57·5
(14·2)
146·3
(22·1)
86·3
(10·5)
190
(57%)
55·6
(13·7)
140·6
(25·9)
82·4
(11·8)
274
(48%)
56·3
(14·2)
143·5
(24·0)
84·3
(11·2)
464
(52%)
VIS 782
(323 men, 
459 women)
56·0
(15·0)
141·6
(23·1)
86·1
(14·2)
152
(47%)
57·1
(15·9)
139·9
(27·9)
83·0
(13·7)
219
(48%)
56·7
(15·1)
140·8
(25·5)
84·6
(13·9)
371
(47%)
Tromsø 9467
(4482 men, 
4985 women)
58·7
(13·1)
146·4
(22·5)
85·7
(13·5)
2690
(60%)
60·4
(14·1)
147·7
(28·1)
83·2
(15·2)
2819
(57%)
59·6
(13·7)
147·1
(25·6)
84·4
(14·5)
5509
(58%)
(Table 1 continues on next page)
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We created two separate vitamin D allele scores: a 
synthesis allele score, created by summing the vitamin 
D-increasing alleles in the genes located upstream 
(DHCR7 and CYP2R1; score range 0–4), and a metabolism 
allele score, created by summing the vitamin D-increasing 
alleles in the genes located downstream (GC and 
Sample size Men Women All participants
Age
(years)
Systolic 
blood 
pressure
(mm Hg)
Diastolic 
blood 
pressure
(mm Hg)
Participants 
with hyper-
tension
Age
(years)
Systolic 
blood 
pressure
(mm Hg)
Diastolic 
blood 
pressure
(mm Hg)
Participants 
with hyper-
tension
Age
(years)
Systolic 
blood 
pressure
(mm Hg)
Diastolic 
blood 
pressure
(mm Hg)
Participants 
with hyper-
tension
(Continued from previous page)
Studies in adults
Whitehall II 5146
(3797 men, 
1349 women)
60·8
(5·9)
132·6
(18·2)
77·7
(11·6)
1556
(48%)
61·2
(6·1)
130·7
(20·6)
76·0
(12·1)
578
(43%)
60·9
(5·9)
132·1
(18·8)
77·2
(11·8)
2134
(41%)
HBCS 1728
(737 men, 
991 women)
61·4
(2·8)
152·9
(22·2)
94·8
(12·2)
571
(77%)
61·6
(3·1)
149·6
(23·9)
90·9
(12·1)
713
(72%)
61·5
(2·8)
150·9
(23·2)
92·5
(12·3)
1284
(74%)
ESTHER 8199
(4598 men, 
3601 women)
62·1
(6·7)
139·4
(20·2)
83·4
(10·2)
2665
(58%)
62·2
(6·5)
140·9
(18·7)
84·3
(10·4)
2260
(63%)
62·1
(6·6)
140·0
(19·6)
83·8
(10·3)
4925
(60%)
LURIC 3287
(2293 men, 
994 women)
61·2
(10·7)
154·2
(23·9)
90·4
(11·9)
2146
(94%)
64·8
(10·2)
154·0
(25·9)
88·0
(12·0)
911
(92%)
62·7
(10·7)
154·2
(24·6)
89·6
(11·9)
3057
(93%)
EAS 907
(448 men, 
459 women)
64·6
(5·6)
141·7
(22·7)
77·5
(11·4)
222
(50%)
64·2
(5·7)
144·5
(24·4)
76·9
(12·9)
245
(53%)
64·4
(5·6)
143·1
(23·6)
77·2
(12·2)
467
(52%)
HCS 2906
(1536 men, 
1370 women)
65·7
(2·9)
139·5
(20·7)
78·4
(11·7)
855
(56%)
66·7
(2·7)
137·8
(22·7)
69·7
(12·1)
741
(54%)
66·1
(2·9)
138·7
(21·7)
74·3
(12·6)
1596
(55%)
ELSA 5054
(2299 men, 
2755 women)
65·9
(9·4)
138·0
(18·7)
77·3
(11·8)
1098
(48%)
66·3
(9·8)
136·6
(20·9)
76·2
(11·3)
1261
(46%)
66·1
(9·4)
137·2
(19·9)
76·7
(11·5)
2359
(47%)
InCHIANTI 1210
(540 men, 
670 women)
67·2
(15·4)
149·6
(21·8)
86·4
(10·0)
400
(74%)
69·1
(15·6)
153·2
(26·6)
86·6
(11·8)
485
(72%)
68·3
(15·4)
151·6
(24·4)
86·5
(11·0)
885
(73%)
PIVUS 995
(498 men, 
497 women)
70·1
(0·2)
150·7
(25·4)
82·5
(12·2)
347
(70%)
70·2
(0·2)
157·7
(26·1)
81·0
(12·2)
366
(74%)
70·2
(0·2)
154·2
(25·9)
81·8
(12·2)
713
(72%)
ULSAM 1129
(1129 men, 
0 women)
71·0
(0·64)
150·8
(21·9)
86·4
(11·7)
790
(70%)
·· ·· ·· ·· 71·0
(0·64)
150·8
(21·9)
86·4
(11·7)
790
(70%)
Health ABC 1554
(826 men, 
728 women)
74·9
(2·9)
137·6
(21·3)
74·7
(12·0)
528
(64%)
74·7
(2·8)
141·6
(23·7)
73·4
(12·6)
474
(65%)
74·8
(2·9)
139·6
(22·5)
74·0
(12·3)
1002
(64%)
MrOS Sweden 2911
(2911 men, 
0 women)
75·4
(3·2)
155·2
(23·9)
83·0
(12·1)
1355
(47%)
·· ·· ·· ·· 75·4
(3·2)
155·2
(23·9)
83·0
(12·1)
1335
(47%)
Studies in adolescents
LISAplus and 
GINIplus
901
(480 men, 
421 women)
10·2
(0·2)
108·5
(9·8)
61·9
(8·1)
·· 10·2
(0·2)
108·8
(9·8)
63·2
(8·5)
·· 10·2
(0·2)
108·6
(9·8)
62·5
(8·3)
··
NFBC 1986 5460
(2769 men, 
2691 women)
16·0
(0·0)
121·1
(12·3)
68·6
(7·9)
·· 16·0
(0·0)
110·2
(10·7)
66·9
(7·2)
·· 16·0
(0·0)
115·6
(11·5)
67·8
(7·6)
··
TRAILS 1289
(619 men, 
670 women)
16·2
(0·06)
122·1
(12·3)
60·3
(6·9)
54
(9%)
16·2
(0·7)
114·5
(11·2)
61·7
(6·8)
17
(3%)
16·2
(0·08)
118·1
(11·7)
61·0
(6·8)
71
(6%)
GOOD 941
(941 men, 
0 women)
18·9
(0·6)
130·7
(13·3)
68·4
(7·9)
240
(26%)
·· ·· ·· ·· 18·9
(0·6)
130·7
(13·3)
68·4
(7·9)
240
(26%)
Data are n, mean (SD), or n (%).
Table 1: Characteristics of the D-CarDia study cohorts, stratiﬁ ed by sex
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Health Sciences 
(K K Lohman MStat), Wake 
Forest School of Medicine, 
Winston-Salem, NC, USA; 
Metabolic Genetics, Novo 
Nordisk Foundation Centre for 
Basic Metabolic Research 
(T S Ahluwalia PhD, 
Prof T I A Sørensen DrMedSci), 
and Copenhagen Prospective 
Studies on Asthma in 
Childhood (T S Ahluwalia), 
Faculty of Health and Medical 
Sciences, University of 
Copenhagen, Copenhagen, 
Denmark; Institute of 
Preventive Medicine, 
Bispebjerg and Frederiksberg 
Hospital, Copenhagen, 
Denmark (T I A Sørensen); 
Danish Pediatric Asthma 
Center, Gentofte Hospital, 
Copenhagen, Denmark 
(T S Ahluwalia); Genetics of 
Complex Traits, University of 
Exeter Medical School, Exeter, 
UK (Dorota Pasko MSc, 
Prof T M Frayling PhD); Centre 
for Population Health Sciences 
(L Zgaga PhD, 
Prof H Campbell MD, 
E Theodoratou PhD, 
R M Fraser PhD, J F Wilson DPhil, 
Prof I Rudan MD, J F Price MD, 
S McLachlan MD), and MRC 
Human Genetics Unit, Institute 
of Genetics and Molecular 
Medicine (V Vitart PhD, 
P Navarro PhD, J E Huﬀ man MSc, 
C Hayward PhD, 
Prof A F Wright PhD), University 
of Edinburgh, Edinburgh, UK; 
Department of Public Health 
and Primary Care, Trinity 
College Dublin, Dublin, Ireland 
(L Zgaga); Institute of 
Epidemiology I, Helmholtz 
Zentrum München—German 
Research Center for 
Environmental Health, 
Neuherberg, Germany 
(E Thiering MSc, 
C M T Tiesler MSc, 
J Heinrich PhD); Division of 
Metabolic Diseases and 
Nutritional Medicine 
(E Thiering), and Institute of 
Medical Informatics, Biometry 
and Epidemiology 
(C M T Tiesler), Ludwig 
Maximilian University of 
Munich, Dr von Hauner 
Children’s Hospital, Munich, 
Germany; Oxford Centre for 
Diabetes, Endocrinology and 
Metabolism 
(Prof M I McCarthy MD), 
Wellcome Trust Centre for 
Human Genetics (M I McCarthy, 
Prof E Ingelsson MD), and NIHR 
Oxford Musculoskeletal
CYP24A1; score range 0–4) of the 25(OH)D metabolite.10,11 
The synthesis allele score can be regarded as an 
instrument for 25(OH)D concentration when testing for 
causal association in mendelian ran domisation analyses 
because it consists of variants that directly aﬀ ect substrate 
availability or synthesis of 25(OH)D. Components 
included in the metabolism score are relevant for the 
transfer and clearance of 25(OH)D and could provide 
insights into the eﬀ ect of vitamin D metabolism on blood 
pressure. However, the use of the metabolism score as a 
formal instrument in mendelian randomisation analyses 
is not possible because of problems with quantiﬁ cation of 
expected associations, pleiotropic eﬀ ects,12,13 and the 
metabolic feedback loops associated with the clearance of 
vitamin D-related metabolites by CYP24A1.17 Investi-
gations with the vitamin D metabolism score were 
therefore exploratory only.
Statistical analysis
Statistical analyses in each of the D-CarDia studies were 
done in accordance with a standard analysis plan. We 
used the natural-log transformation for 25(OH)D 
concentrations to achieve a closer approximation of the 
normal distribution, and to remove non-linearity in the 
association with the outcomes. Additive models with 
systolic blood pressure, diastolic blood pressure, and 
D-CarDia studies contributing data to 
phenotype-outcome, genotype-outcome, 
and genotype-phenotype analyses (with 
SNPs, blood presssure outcomes, and 
25[OH]D measurements)
Studies in adults
58BC (UK, n=7152)
DOPS (Denmark, n=1684)
DPP* (USA, n=1998)
ESTHER† (Germany, n=8199)
FHS (USA, n=5654)
GENMETS (Finland, n=868)
Health ABC (USA, n=1554)
HCS (UK, n=2906)
InCHIANTI (Italy, n=1210)
LURIC (Germany, n=3287)
MrOS (Sweden, n=2911)
NFBC66 (Finland, n=4488)
PIVUS (Sweden, n=995)
TROMSO (Norway, n=9467)
TWINSUK (UK, n=2392)
ULSAM (Sweden, n=1129)
Young Finns (Finland, n=2443)
17 studies, total n=58 337
(with 25[OH]D measurements, n=49 346)
Studies in adolescents (secondary analyses)
GINILISA (Germany, n=901)
GOOD (Sweden, n=941)
Two studies, total n=1842
(with 25[OH]D measurements, n=1776)
D-CarDia studies contributing data to 
genotype-outcome analyses only (with 
SNPs and blood pressure outcomes, but 
no 25[OH]D measurements)
Studies in adults
EAS (UK, n=907)
ELSA (UK, n=5054)
GOYA (Denmark, n=1465)
HBCS (Finland, n=1728)
KORCULA (Croatia, n=901)
Lifelines (Netherlands, n=13 235)
NESDA (Netherlands, n=1717)
NPHSII (UK, n=2771)
MRC NSHD (UK, n=2674)
ORKNEY (UK, n=718)
PREVEND† (Netherlands, n=3649)
SPLIT (Croatia, n=498)
VIS (Croatia, n=782)
WHII (UK, n=5146)
14 studies, total n=41 245
Studies in adolescents (secondary analyses)
NFBC86 (Finland, n=5460)
TRAILS (Netherlands, n=1289)
Summary
D-CarDia studies in adults
31 studies, n=99 582; 50% of participants with 25(OH)D measurements 
D-CarDia studies in adults and ICBP (overlapping studies removed)
53 studies, n=146 581; 32% of participants with 25(OH)D measurements
D-CarDia studies in adults, CHARGE, and Global BPGen (overlapping studies removed)
50 studies, n=142 255; 33% of participants with 25(OH)D measurements 
D-CarDia studies in adolescents (secondary analyses)
Four studies, n=8591; 21% of participants with 25(OH)D measurements 
Consortia contributing data to genotype-outcome 
analyses only (with SNPs and blood pressure 
outcomes, but no 25[OH]D measurements)
ICBP (29 studies, n=69 395)
CHARGE (6 studies, n=29 136)
Global BPGen (16 studies, n=34 433)
Figure 1: Flow chart showing the sample sizes available at each stage of the meta-analyses
25(OH)D=25-hydroxyvitamin D. ICBP=International Consortium for Blood Pressure. CHARGE=Cohorts for Heart and Aging Research in Genomic Epidemiology. Global 
BPGen=Global Blood Pressure Genetics. *Did not contribute data to analyses with the synthesis score single-nucleotide polymorphisms (SNPs) because of 
unavailability of the CYP2R1 SNP. †Did not contribute data to analyses with the metabolism score SNPs because of unavailability of GC or CYP24A1 SNPs.
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(Prof C Cooper FMedSci, 
Prof N Arden DM), University of 
Oxford, Oxford, UK; Oxford 
NIHR Biomedical Research 
Centre, Oxford, UK 
(M I McCarthy); National Heart, 
Lung, and Blood Institute’s 
Framingham Heart Study, 
Framingham, MA, USA 
(J Dupuis); Institute of 
Biomedicine 
(Prof K H Herzig MD), Biocenter 
Oulu (K H Herzig, S Sebert PhD, 
M-R Järvelin), and Institute of 
Health Sciences (M-R Järvelin, , 
A C Alves, S Sebert), University 
of Oulu, Oulu, Finland; Medical 
Research Center Oulu 
(K H Herzig), and Obstetrics and 
Gynecology, Department of 
Clinical Sciences (A Pouta MD), 
and Unit of Primary Care 
(M-R Järvelin), Oulu University 
Hospital, Oulu, Finland; 
National Institute for Health 
and Welfare, Oulu, Finland 
(A Pouta, M-R Järvelin); Finnish 
Institute of Occupational 
Health, Helsinki, Finland 
(J Laitinen PhD); Medical Clinic V 
(Nephrology, Hypertensiology, 
Rheumatology, Endocrinology, 
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Medical Faculty, University of 
Heidelberg, Mannheim, 
Germany (M E Kleber PhD, 
Prof W März MD); MRC 
Lifecourse Epidemiology Unit, 
University of Southampton, 
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(K Jameson MSc, C Cooper, 
N Arden, Prof C Osmond PhD); 
Research Centre of Applied and 
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Medicine, University of Turku, 
Turku, Finland 
(Prof O Raitakari MD); 
Department of Clinical 
Physiology and Nuclear 
Medicine, Turku University 
Hospital, Turku, Finland 
(O Raitakari); Institute for 
Molecular Medicine Finland 
(Prof S Ripatti PhD, E Tikkanen), 
Hjelt Institute (S Ripatti, 
E Tikkanen), Institute of 
Behavioural Sciences 
(J Lahti PhD), and Department 
of General Practice and Primary 
Health Care 
(Prof J G Eriksson MD), 
University of Helsinki, Helsinki, 
Finland; Department of 
Psychiatry, EMGO Institute, VU 
University Medical Centre, 
Amsterdam, Netherlands 
(Prof B W Penninx PhD); Center 
for Human Genetic Research 
and Diabetes Research Center 
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hypertension as outcomes were adjusted for age, age-
squared, BMI, sex, geographical region, or principal 
components (as relevant for the study); models with 
25(OH)D concentration as the outcome were additionally 
adjusted for month of blood sample collection and 
laboratory batch, as relevant.
With respect to the phenotypic analyses, confounding 
factors that aﬀ ect 25(OH)D concentrations were assessed 
previously with the 1958 British birth cohort10 and in 
selected D-CarDia studies with individual-level data 
(appendix pp 26–28). To assess the association of 
25(OH)D concentration with systolic blood pressure, 
diastolic blood pressure, and hypertension, the 
investigators of each of the D-CarDia studies did linear 
regression analyses, adjusting for the key covariates as 
adjusted for in the additive models, and the models were 
repeated stratiﬁ ed by sex (appendix p 39).
With respect to genetic eﬀ ects on 25(OH)D con-
centration, the eﬀ ect allele was the 25(OH)D-increasing 
allele, as established by the SUNLIGHT Consortium.9 
We tested the association of the four individual 
vitamin D-related genetic markers, and the two vitamin D 
allele scores, with 25(OH)D concentrations using linear 
regression models, adjusting for the same covariates as 
adjusted for in the additive models. We tested for 
associations of the synthesis score, and its components, 
with several confounders: age, sex, season, BMI, total 
cholesterol, and triglycerides (appendix pp 29–32). To 
examine variations that could aﬀ ect the validity of the 
instruments, we used meta-regression to assess hetero-
geneity in the associations between the SNPs and 
25(OH)D concentration by study-level factors: sex, age, 
method of blood pressure measurement (manual, 
automated, or random-zero manometer), proportion of 
hypertensive participants, geographical region (UK, 
central and southern Europe, North America, 
Scandinavia, or Finland), and BMI. Models were repeated 
with adjustment for serum triglycerides and total 
cholesterol (to exclude pleiotropic eﬀ ects through lipid 
metabolism, since 25[OH]D is a cholesterol derivative) in 
addition to the the covariates as adjusted for in the 
additive models when examining systolic blood pressure, 
diastolic blood pressure, and hypertension as outcomes.
To examine the strength of the synthesis allele score as an 
instrument, we calculated the F-statistic from the proportion 
of variation in the respective phenotype (R²) explained by 
the allele score (F-statistic=(R² × (n – 2))/(1 – R²)].18 We used 
the inverse of the F-statistic to calculate the relative bias of 
the instrumental variable ratio compared with ordinary 
least-squares linear regression.19 Because external weights 
were not available and the use of internal weights could bias 
the instrumental variable results, we did an unweighted 
allele score analysis for the vitamin D SNPs (appendix p 39).
We did the formal mendelian randomisation analyses to 
estimate the possible causal relationship between 
25(OH)D concentration and systolic blood pressure, 
diastolic blood pressure, and hypertension using the 
instrumental variable ratio method.20 To estimate the 
instrumental variable ratio for the eﬀ ect of 25(OH)D 
concentration on systolic blood pressure, diastolic blood 
pressure, and hypertension, we divided the meta-analysed 
association of the vitamin D synthesis allele score with 
systolic blood pressure, diastolic blood pressure, and 
hypertension by the association of vitamin D synthesis 
allele score with 25(OH)D concentration. We estimated 
the variance for the instrumental variable ratio using a 
Taylor expansion.21
We used summary statistics for the four vitamin D SNPs 
from the ICBP,14 Global BPGen15 and CHARGE16 
consortia to increase the statistical power of our analyses 
of the association between the vitamin D allele scores 
and blood pressure outcomes. We used an approximation 
method that has been previously described14 to combine 
SNPs into the synthesis and metabolism allele scores.
In the presence of heterogeneity of association between 
the studies, we used random-eﬀ ects meta-analyses; 
otherwise, we tested ﬁ xed-eﬀ ects models. We investigated 
sources of heterogeneity with univariate meta-regression 
models.
Four studies in the D-CarDia collaboration are in 
adolescents (aged 10–20 years, n=8591). The main meta-
analyses were restricted to adult populations (aged 
31–92 years, n=99 582), and only exploratory analyses 
were done in adolescents because of insuﬃ  cient sample 
sizes (appendix pp 20, 33, and 39).
We did additional sensitivity analyses to examine the 
eﬀ ect of adjusting for lipids (appendix p 34) of the quality 
of genetic information (appendix p 35), and of the 
adjustment applied for the use of antihypertensive drugs 
(appendix p 36), as well as to compare the two-stage 
instrumental variable ratio method with the 
meta-analysis of study-speciﬁ c instrumental variable 
ratios (appendix p 37).
All meta-analyses were done at the UCL Institute of 
Child Health (University College London, London, UK) 
with Stata version 12.
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
summary data from all studies and had ﬁ nal responsibility 
for the decision to submit for publication.
Results
All four vitamin D-related SNPs were strongly associated 
with 25(OH)D concentrations (p<2·22 × 10–¹² for all 
comparisons; appendix p 33). As previously reported,10,11 
the synthesis and metabolism allele scores were strongly 
associated with 25(OH)D concentrations (synthesis score 
β 2·83%, 95% CI 2·48–3·18, p=2·70 × 10–⁵⁵, R²=0·5%; 
metabolism score β 5·38%, 4·67–6·08, p=5·93 × 10–⁵⁰, 
R²=1·4%; appendix p 33). There was no evidence for 
heterogeneity in the association between the synthesis 
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score and 25(OH)D concentration (I²=0%, p=0·48). 
Heterogeneity was seen for the metabolism score (I²=57%, 
p=0·003), with evidence of variation in the association 
between metabolism score and 25(OH)D concentration 
by mean study BMI (p=0·02). The F-statistic for the 
synthesis allele score was 219·7, which suggests a strong 
composite instrument. The relative bias of the 
instrumental variable ratio compared with ordinary 
least-square linear regression was small (0·5%).
Increased 25(OH)D concentrations were associated 
with reduced systolic blood pressure (β per 10% change, 
–0·12 mm Hg, 95% CI –0·20 to –0·04; p=0·003) and 
reduced odds of hypertension (odds ratio [OR] 0·98, 
95% CI 0·97–0·99; p=0·0003); however, we did not see an 
association between 25(OH)D concentration and diastolic 
blood pressure (β –0·02 mm Hg, –0·08 to 0·03; p=0·37; 
appendix p 40). Despite evidence for heterogeneity in the 
phenotypic association between 25(OH)D concentration 
and the outcomes within the studies done in adults 
(systolic blood pressure, I²=73%, p=9·19 × 10–⁰⁷; diastolic 
blood pressure, I²=78%, p=5·00 × 10–⁰⁹; hypertension, 
I²=62%, p=0·001), the observed association between 
25(OH)D concentration and systolic blood pressure, 
diastolic blood pressure, or hypertension between studies 
did not vary by age (meta-regression p≥0·09 for all 
comparisons), sex (meta-regression p≥0·65), method of 
blood pressure measurement (meta-regression p≥0·14), 
geographical region (meta-regression p≥0·39), or BMI 
(meta-regression p≥0·10). However, for the association 
between 25(OH)D concentration and diastolic blood 
pressure, there was variation across the proportion of 
hypertensive participants (meta-regression p=0·01).
In the meta-analyses of the D-CarDia studies (n=108 173), 
there was no association of the synthesis allele score with 
systolic blood pressure (β per 25[OH]D-increasing allele, 
–0·10 mm Hg, 95% CI –0·23 to 0·02; p=0·11), diastolic 
blood pressure (β –0·07 mm Hg, –0·15 to 0·01; p=0·07), 
or hypertension (OR 0·99, 95% CI 0·97–1·00; p=0·08). 
After increasing the sample size by meta-analysing the 
D-CarDia results with the summary data from the ICBP 
consortium (total n=146 581, after exclusion of overlapping 
studies), the precision of estimation was improved, but 
the estimated strengths of these associations remained 
unchanged. The synthesis score was associated with both 
systolic blood pressure (β –0·10 mm Hg, –0·21 to –0·0001; 
p=0·0498) and diastolic blood pressure (β –0·08 mm Hg, 
Figure 2: Meta-analysis of D-CarDia studies with summary data from the ICBP, CHARGE, and Global BPGen consortia
Association of the synthesis score with systolic blood pressure, diastolic blood pressure, and hypertension. Includes data for 146 581 individuals, after exclusion of overlapping studies. The area of the 
grey boxes around a point estimate is proportional to the study’s weight in the meta-analysis. ICBP=International Consortium for Blood Pressure. CHARGE=Cohorts for Heart and Aging Research in 
Genomic Epidemiology. Global BPGen=Global Blood Pressure Genetics.
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–0·15 to –0·02; p=0·01; ﬁ gure 2). For hypertension as the 
outcome, we meta-analysed the summary results from the 
CHARGE and Global BPGen consortia with the study 
results from adults in the D-CarDia collaboration 
(total n=142 255, after exclusion of overlapping studies). 
This analysis showed that the synthesis score was 
associated with hypertension (OR for increase per allele, 
0·98, 0·96–0·99; p=0·001; ﬁ gure 2). The metabolism 
allele score was not associated with any blood pressure 
outcomes. For analyses with maximum samples sizes, 
β for systolic blood pressure was –0·001 mm Hg 
(95% CI –0·12 to 0·12; p=0·99), β for diastolic blood 
pressure was 0·005 mm Hg (–0·07 to 0·08; p=0·90), and 
the OR for hypertension was 0·99 (0·98–1·01; p=0·48; 
appendix p 44).
In the instrumental variable analysis, in which the 
synthesis score was used as an instrument, the direction 
of association between 25(OH)D concentration and all 
outcomes was compatible with that suggested by the 
observational phenotypic associations (table 2). Every 
10% relative increment in genetically instrumented 
25(OH)D concentration was associated with 0·29 mm Hg 
lower diastolic blood pressure (95% CI 0·07 to 0·52; 
p=0·01) and a 0·37 mm Hg lower systolic blood pressure 
(–0·003 to 0·73; p=0·052). Every 10% increment in 
25(OH)D concentration was associated with an 
8·1% reduced odds of hypertension (OR 0·92, 95% CI 
0·87–0·97; p=0·002) in the instrumental variable ratio 
analyses (table 2, ﬁ gure 3).
The CYP2R1 SNP was individually associated with 
reduced diastolic blood pressure (per allele, β –0·09 mm Hg, 
95% CI –0·18 to –0·01; p=0·03) and reduced odds of 
hypertension (OR for increase per allele, 0·98, 0·96–1·00; 
p=0·02), but no individual associations were seen for the 
DHCR7 SNP, or either of the downstream metabolism 
SNPs (GC and CYP24A1), with any of the blood pressure 
outcomes (appendix pp 41−43).
Discussion
The results of our mendelian randomisation analysis 
provide evidence for a causal eﬀ ect of low vitamin D status 
on increasing blood pressure and risk of hypertension. 
This ﬁ nding lends support to continued eﬀ orts to prevent 
vitamin D deﬁ ciency. In view of the costs and side-eﬀ ects 
associated with antihypertensive drugs, the potential to 
reduce hypertension by vitamin D is very attractive. 
However, because we cannot exclude the possibility that 
our ﬁ ndings were caused by chance, they need to be 
replicated in an independent, similarly powered study.
Evidence from randomised controlled trials to assess 
the eﬀ ectiveness of vitamin D supplementation in 
reducing blood pressure have not provided consistent 
evidence of a beneﬁ t.1 In subgroup analyses done within 
meta-analyses of these trials,5,22 some reductions in 
diastolic blood pressure were reported for participants 
with hypertension or cardiometabolic disease, and when 
studies that used higher doses were compared with 
those that used lower doses of vitamin D.23 Although the 
investigators of one study6 reported dose-dependent 
reductions in systolic blood pressure after 3 months of 
supplementation with 1000 IU, 2000 IU, and 4000 IU of 
vitamin D per day (0·66, 3·4, and 4·0 mm Hg, 
respectively), no eﬀ ect was seen in another trial24 in 
which participants were given a bolus supplement of 
100 000 IU every 3 months. These inconsistencies could 
be attributed to diﬀ erences in the mode of administration, 
dose, and duration of supplementation, or to baseline 
diﬀ erences in 25(OH)D concentrations or blood 
pressure, or other sources of heterogeneity between the 
studies. Thus, the evidence remains inconclusive. 
Nevertheless, these exploratory randomised controlled 
trials have paved the way for large trials (with upwards of 
18 000 participants) that are being undertaken to 
examine the beneﬁ ts of vitamin D for the prevention of 
cardiovascular disease outcomes.25
Our ﬁ ndings are biologically plausible. Inappropriate 
activation of the renin-angiotensin system increases 
blood pressure and the risk of cardiovascular disease.26 
Figure 3: Mendelian randomisation triangulation for hypertension
Instrumental variable ratio calculation done with the natural log of the odds (βZY). OR=odds ratio. 
25(OH)D=25-hydroxyvitamin D.
ORXY=0·98 (95% CI 0·97–0·99)
OR for observed association of 25(OH)D 
(per 10% increase) with hypertension
Exposure (X) 
25(OH)D concentration
Outcome (Y)
Hypertension
ORZY=0·98 (95% CI 0·96–0·99)
OR for observed association of synthesis  
score (per allele) with hypertension
Instrument (Z)
Synthesis score
ORIV=0·92 (95% CI 0·87–0·97)
Estimated 8·1% reduction in odds of hypertension 
for a 10% increase in 25(OH)D using synthesis score 
as an instrumental variable
βZX=2·83% (95% CI 2·48–3·18)
Observed association of the synthesis score 
(per allele) with 25(OH)D concentration
Estimate from 
phenotypic analyses, 
per 10% increase in 
25(OH)D concentration
Synthesis score 
with outcome, 
per allele
Instrumental variable 
estimate for causal eﬀ ect, 
per 10% increase in 
25(OH)D concentration
Coeﬃ  cient*
(95% CI)
p value Coeﬃ  cient*
(95% CI)
 Coeﬃ  cient*
(95% CI)
p value
Systolic blood pressure 
(mm Hg)
–0·12 
(–0·20 to –0·04)
0·003 –0·10 
(–0·21 to –0·0001)
–0·37
(–0·73 to 0·003)
0·052
Diastolic blood pressure 
(mm Hg)
–0·02 
(–0·08 to 0·03)
0·374 –0·08
(–0·15 to –0·02)
–0·29
(–0·52 to –0·07)
0·01
Hypertension (odds ratio) 0·98 
(0·97 to 0·99)
0·0003 0·98
(0·96 to 0·99)
0·92
(0·87 to 0·97)
0·002
Results include the D-CarDia studies (in adults only) and consortium summary statistics from the International 
Consortium for Blood Pressure (ICBP), the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) 
consortium, and the Global Blood Pressure Genetics (Global BPgen) consortium. Association of the synthesis score 
with 25-hydroxyvitamin D (25[OH]D): coeﬃ  cient per allele, 2·83% (95% CI 2·48–3·18). *Coeﬃ  cient represents the 
diﬀ erence in blood pressure (mm Hg) or the odds ratio.
 Table 2: Summary of coeﬃ  cients for instrumental variable ratio analyses, with the synthesis score as an 
instrumental variable
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Studies in animals have shown that 1,25-dihydroxy-
vitamin D (calcitriol, 1,25[OH] 2D) suppresses the 
expression of the renin gene by a vitamin D 
receptor-dependent mechanism, thereby lowering blood 
pressure.27 In an open-label, blinded-endpoint trial28 in 
101 patients with chronic heart failure who were 
randomly assigned to receive 2000 IU of oral vitamin 
D3 per day for 6 weeks or control (no treatment), 
treatment led to a signiﬁ cant decrease in plasma renin 
activity (p=0·002) and concentration (p=0·02). However, 
some ﬁ ndings have raised concerns about whether 
activation of the renin-angiotensin system has a role in 
the vitamin D-deﬁ cient state in human beings.29 
Vitamin D metabolites could also exert antihypertensive 
eﬀ ects through various other molecular mechanisms. 
Vitamin D is indirectly related to blood pressure through 
its regulation of calcium absorption from the gut and its 
interaction with parathyroid hormone in the 
maintenance of calcium homeostasis. The reno-
protective and anti-inﬂ ammatory actions of vitamin D 
metabolites and their analogues suggest a possible role 
for vitamin D deﬁ ciency in cardiovascular morbidity 
and mortality in patients with chronic kidney disease.30 
Furthermore, adipocyte inﬂ ammation has a crucial role 
in hypertension: in an in-vitro study,31 1,25(OH)2D 
inhibited lipopolysaccharide-stimulated cytokine 
secretion in two human adipocyte models through 
direct inhibition of nuclear factor-κB.
On the basis of our eﬀ ect size estimates, the genetic 
associations of the synthesis allele score with systolic or 
diastolic blood pressure were less pronounced than that 
seen for hypertension (represented as a binary trait). 
This ﬁ nding might suggest that adequate 25(OH)D 
concentrations are particularly important for the 
prevention of hypertension as a clinical outcome. This 
interpretation is also supported by the results of 
sensitivity analyses in normotensive individuals, which 
showed that both the phenotypic association and the 
genetically indexed association between 25(OH)D 
concentrations and blood pressure were substantially 
weaker in this subgroup than in the full sample (data 
not shown).
Although the mendelian randomisation approach is 
helpful in testing for underlying causality,20 an imbalance 
in the possible overestimation or underestimation of the 
genetic associations for the outcome and exposure could 
aﬀ ect the quantiﬁ cation of the eﬀ ect.32 The weaker 
association with blood pressure than with hypertension 
could also reﬂ ect a greater measurement error or 
heterogeneity in the assessment of gradual increases 
across the range of the blood pressure distribution, 
compared with the classiﬁ cation of hypertension by raised 
blood pressure or use of antihypertensive drugs. Such 
noise or heterogeneity in the blood pressure measurements 
in our meta-analyses could also account for why the 
estimated strength of the associations between 25(OH)D 
concentrations and blood pressure outcomes were weaker 
than we would have expected on the basis of previous 
observational analyses or of power calculations that were 
done with data from one of the D-CarDia studies 
(1958 British birth cohort, n=6877).10
The main strength of our study is in the large sample 
size (up to n=146 581), which allowed us to assess the 
consistency of associations across several studies and to 
gain suﬃ  cient power for conclusive analyses. This study 
shows the beneﬁ ts of the mendelian randomisation 
approach: although the phenotypic associations between 
25(OH)D concentrations and blood pressure or 
hypertension were very heterogeneous across the 
studies, notably less heterogeneity was seen for the 
genetic associations. Age and adiposity are issues that 
would be expected to aﬀ ect 25(OH)D concentrations and 
bias the phenotypic association it might have with blood 
pressure, but participating studies included both young 
and old cohorts, and both lean and obese participants. 
By contrast, genetic variants used in mendelian 
randomisation would be expected to reﬂ ect lifelong 
diﬀ erences in 25(OH)D concentrations and would 
therefore be less aﬀ ected by temporal variations in 
individual characteristics.
Potential limitations with the mendelian randomisation 
approach include the requirement of large sample sizes, 
the possibility of population stratiﬁ cation, canalisation, 
pleiotropy, and an inability to generalise ﬁ ndings to people 
in other ethnic groups. A limitation of our study was that 
we only looked at associations with blood pressure and 
hypertension, and whether these associations are related 
to diﬀ erences in the risks of rarer disease outcomes 
remains uncertain. Population stratiﬁ cation is unlikely to 
have had a major eﬀ ect on our main ﬁ ndings, since 
participants were all of European descent, and we adjusted 
for geographical region and principal components from 
the population stratiﬁ cation analysis in the statistical 
models.
The synthesis or metabolism SNPs might have led to 
biological adaptations during development (ie, canal-
isation),8 although this possibility seems unlikely in view 
of the similar associations with 25(OH)D seen in the 
analyses done in adolescents and adults. Pleiotropic 
eﬀ ects, wherein the genetic instruments might aﬀ ect other 
metabolic pathways independent of their inﬂ uence on 
25(OH)D concentration, are more likely. Our main 
instrument was a composite score consisting of two 
independent SNPs. Although diﬀ erential associations 
between the components included in the score can suggest 
a possible pleiotropic eﬀ ect, in our case the associations for 
CYP2R1 and DHCR7 were similar for all three outcomes 
(appendix p 38). Furthermore, because 25(OH)D is a 
secosteroid, we explicitly sought to exclude pleiotropic 
eﬀ ects through lipid metabolism by adjusting for serum 
triglycerides and total cholesterol in addition to other 
covariates, and noted no diﬀ erences in our ﬁ ndings 
(appendix p 34). However, pleiotropy is an issue with the 
metabolism variants included in our secondary analyses. 
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